An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors

Trial Profile

An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Tivozanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top